KKR, Ampersand Capital in joint bid for Oxford Immunotec: sources

A consortium of private equity firms KKR & Co Inc and Ampersand Capital Partners has approached Oxford Immunotec Global Plc , a medical diagnostics company that develops tests to identify tuberculosis, with a $400 million acquisition offer, people familiar with the matter said on Thursday.

…read more

Discover Tomorrow’s Winning Stocks!
Get our latest stock reports before everyone else! Actionable news, and breakout stocks w multi-bagger upside potential — delivered directly to your inbox.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

Source:: Reuters – Business News